Welcome to the e-CCO Library!

OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Ben-Horin1, J. Leszczyszyn2, R. Dudkowiak2, A. Lahat3, B. Gawdis-Wojnarska4, A. Pukitis5, M. Horynski6, K. Farkas7, J. Kierkus8, M. Kowalski9, B.D. Ye10, W. Reinisch11, S.J. Lee12, S.H. Kim13, M.R. Kim13, Y.A. Kim13, H.N. Kim14, S. Schreiber15

Created: Thursday, 30 January 2020, 10:12 AM
OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study
Year: 2022
Source: ECCO'22
Authors: Danese, S.(1);Panaccione, R.(2);Rubin, D.T.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Panés, J.(7);Gonzalez, S.(8);Weisel, K.(8);Sahoo, A.(8);Frustaci, M.E.(8);Yang, Z.(8);Sandborn, W.J.(9);Afzali, A.(10);Hisamatsu, T.(11);Andrews, J.M.(12);Feagan, B.(13); on behalf of the GALAXI-1 investigators
Created: Friday, 11 February 2022, 3:52 PM
OP24: Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Fumery*1, L. Peyrin-biroulet2, S. Nancey3, R. Altwegg4, P. Veyrard5, G. Bouguen6, S. Viennot7, F. Poullenot8, J. Filippi9, A. Buisson10, A. Bozon11, C. Gilletta12, F. Brazier13, L. Pouillon2, B. Flourié14, L. Boivineau4, L. Siproudhis6, D. Laharie8, X. Roblin15, X. Treton11

Created: Friday, 22 February 2019, 9:41 AM
OP24: Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
Year: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Vermeire , S.(2);Zhou, W.(3);Pangan, A.(4);Siffledeen, J.(5);Hébuterne, X.(6);Nakase, H.(7);Higgins, P.(8);Chen, M.H.(9);Sanchez-Gonzalez, Y.(3);Huang, B.(3);Xie, W.(4);Liu, J.(4);Weinreich, M.(4);Pannaccione, R.(10)
Created: Wednesday, 2 June 2021, 4:12 PM
OP24: Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liu, Z.(1)*;Le, K.(1);Zhou, X.(1);Alexander, J.(1);Lin, S.(2);Bewshea, C.(2);Chanchlani, N.(2);Nice, R.(3);McDonald, T.(3);Lamb, C.(4);Sebastian, S.(5);Kok, K.(6);Lees, C.(7);Hart, A.(1);Pollok, R.(8);Boyton, R.(9);Altmann, D.(10);Pollock, K.(9);Goodhand, J.(2);Kennedy, N.(2);Ahmad, T.(2);Powell, N.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP25 Biologics before surgery for IBD: Are they associated with post-operative infectious outcomes? Results from the national surgical quality improvement programme inflammatory bowel disease collaborative
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Holubar1, X. Jai1, T. Hull1, N. Hyman2, S. Ramamoorthy3, S. Einsenstein3, National Surgical Quality Improvement Program Inflammatory Bowel Disease Collaborative

Created: Thursday, 30 January 2020, 10:12 AM
OP25: Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Peyrin-Biroulet, L.(1);Dotan, I.(2,3);Hibi, T.(4);Taliadouros, V.(5);Oortwijn, A.(5);Zhao, S.(6);Zhang, J.(6);Hsieh, J.(6);Feagan, B.(7,8)
Created: Wednesday, 2 June 2021, 4:12 PM
OP25: Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials
Year: 2022
Source: ECCO'22
Authors: Ferrante, M.(1);Cao, Q.(2);Fujii, T.(3);Rausch, A.(4);Neimark, E.(5);Song, A.(6);Wallace, K.(6);Kligys, K.(7);Zhou, Q.(8);Kalabic, J.(9);Feagan, B.G.(10);
Created: Friday, 11 February 2022, 3:52 PM
OP25: Prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative data
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van Linschoten, R.(1,2,3)*;van Leeuwen, N.(2);Hazelzet, J.A.(2);van der Woude, C.J.(3);van Noord, D.(4);West, R.L.(4);
Created: Friday, 14 July 2023, 10:43 AM
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Dreesen*1, F. Baert2, D. Laharie3, P. Bossuyt4, Y. Bouhnik5, A. Buisson6, G. Lambrecht7, E. Louis8, B. Oldenburg9, B. Pariente10, M. Pierik11, C. J. van der Woude12, G. D’Haens13, S. Vermeire14,15, A. Gils1

Created: Friday, 22 February 2019, 9:41 AM
OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Iacucci1, S.C. Smith2, A. Bazarova2, U.N. Shivaji1, P. Bhandari3, R. Cannatelli2, M. Daperno4, J.G. Ferraz5, M. Goetz6, X. Gui7, B. Hayee8, G. De Hertogh9, M. Lazarev10, J. Li11, O.M. Nardone2, V. Occhipinti12, R. Panaccione5, A. Parra-Blanco13, L. Pastorelli12, T. Rath14, G. Tontini15, M. Vieth16, V. Villanacci17, D. Zardo18, R. Kiesslich19, R. Bisschops20, S. Ghosh1

Created: Thursday, 30 January 2020, 10:12 AM
OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
Year: 2022
Source: ECCO'22
Authors: D'Haens, G.(1);Kobayashi, T.(2);Morris, N.(3);Lissoos, T.(3);Hoover, A.(3);Li, X.(3);Arora, V.(3);Milch, C.(3);Sandborn, W.J.(4);Sands, B.E.(5);
Created: Friday, 11 February 2022, 3:52 PM
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Aguas Peris, M.(1,2)*;Del Hoyo, J.(1,2);Vicente, R.(3,4);Barreiro-de Acosta, M.(5);Melcarne, L.(6);Hernández-Camba, A.(7);Alfambra, E.(8,9);Madero, L.(10,11);Sicilia, B.(12);Chaparro, M.(13,14,15,16);Martín-Arranz, M.D.(14,17,18);Pajares, R.(19);Mesonero, F.(20);Mañosa, M.(16,21);Martínez, P.(22);Chacón , S.(23);Tosca, J.(24);Marín, S.(25,26);Sanromán, L.(27,28,29,30);Calvo, M.(31);Monfort, D.(32);Saiz, E.(33);Zabana, Y.(16,34);Guerra, I.(35);Varela, P.(36);Faubel, R.(37,38,39);Corsino, P.(3,4);Porto-Silva, S.(5);Brunet, E.(6);Gutiérrez, A.(10,11,16);Nos, P.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vermeire1, J-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers*10, R. A. Lirio10, E. V. LoftusJr11

Created: Friday, 22 February 2019, 9:41 AM
OP26: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Year: 2021
Source: ECCO'21 Virtual
Authors: Schreiber , S.W.(1);Ferrante , M.(2);Panaccione , R.(3);Colombel , J.F.(4);Hisamatsu , T.(5);Lim , A.(6);Lindsay , J.O.(7);Rubin , D.T.(8);Sandborn , W.J.(9);Neimark , E.(10);Song , A.P.(10);Liao , X.(10);Feng , T.(10);Berg , S.(10);Wallace , K.(10);D’Haens , G.R.(11)
Created: Wednesday, 2 June 2021, 4:12 PM
OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Ferrante1, B.G. Feagan2, J. Panés3, F. Baert4, E. Louis5, O. Dewit6, A. Kaser7, W.R. Duan8, D. Gustafson9, X. Liao10, K. Wallace9, J. Kalabic11, G.R. D’Haens12

Created: Thursday, 30 January 2020, 10:12 AM
OP27: A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy Volunteers
Year: 2022
Source: ECCO'22
Authors: Lee, C.(1);Ramaiya, A.(1);Tang , Y.(1);Sapone, A.(2);Shan , K.(3);Randle, A.(4);Grundy, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rubín De Célix, C.(1)*;Martín de Carpi, J.(2);Pujol, G.(2);Palomino, L.(3);Velasco, M.(3);Martín-Masot, R.(4);Navas-López, V.M.(4);Ricart, E.(5);Casanova, M.J.(1);Rodríguez Martínez, A.(6);Leo, E.(7);Alcaraz, A.(8);Mañosa, M.(9);Hernández, V.(10);Fernández, R.(10);Sánchez, C.(11);Menchén, L.(12);Mesonero, F.(13);Barreiro-De Acosta, M.(14);Martinon, N.(15);Tejido Sandoval, C.(16);Rendo Vázquez, A.(17);Corsino, P.(18);Vicente, R.(18);Hernández-Camba, A.(19);Alberto Alonso, J.R.(20);Alonso-Abreu, I.(21);Castro Millán, A.M.(22);Peries Reverter, L.(23);Castro, B.(24);Fernández-Salgado, E.(25);Busto Cuiñas, M.M.(26);Benítez, J.M.(27);Madero, L.(28);Clemente, F.(29);Riestra, S.(30);Jiménez-Treviño, S.(31);Boscá, M.(32);Chaparro, M.(1);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP27: Has been withdrawn
Year: 2021
Source: ECCO'21 Virtual
Authors: Has been withdrawn
Created: Wednesday, 2 June 2021, 4:12 PM
OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. van Unen1, N. Li1, T. Abdelaal2,3, Y. Kooy-Winkelaar1, L. Ouboter*1,4, G. Beyrend1, T. Höllt3,6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10,11, A. van der Meulen - de Jong4, F. Koning1

Created: Friday, 22 February 2019, 9:41 AM